Advertisement
Advertisement
U.S. markets open in 9 hours 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Vyant Bio, Inc. (VYNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5580+0.0046 (+0.83%)
At close: 04:00PM EDT
0.5600 +0.00 (+0.36%)
After hours: 05:43PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.5534
Open0.5524
Bid0.5600 x 1200
Ask0.6500 x 3100
Day's Range0.5524 - 0.5700
52 Week Range0.5000 - 3.2400
Volume21,076
Avg. Volume24,993
Market Cap16.374M
Beta (5Y Monthly)N/A
PE Ratio (TTM)0.45
EPS (TTM)1.2400
Earnings DateNov 09, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VYNT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vyant Bio, Inc.
    Analyst Report: Qiagen N.V.Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022

    -Invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ CHERRY HILL, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines h

  • GlobeNewswire

    Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be presenting at the H.C. Wainwright 24th A

  • GlobeNewswire

    Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

    Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement and guidance from the International Rett Syndrome FoundationContinued progress with efforts towards the divestiture of the vivoPharm businessProgress with licensing our iPSC technology to transition key product sales customers Financial Highlights $11.7 mi

Advertisement
Advertisement